LECT2 and cancer: Indeed, we provided evidence that loss of Lect2 substantially impairs the therapeutic efficacy of checkpoint blockade in cancer immunotherapy for murine ID8 EOC, which suggests that loss of Lect2 poses a significant obstacle to EOC immune therapy.